Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 1 Published - 14:00 UTC    08:00 EST    20-September-2000      
Issue 160 Next Update - 14:00 UTC 08:00 EST    21-September-2000      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya

Back To Vidyya Today In Vidyyasm

Newsletter Summary For 20-September-2000:

A class of nutrients, isothiocyanates, found only in cruciferous vegetables -- broccoli, cauliflower, cabbage, watercress, bok choy, among others -- was protective against lung cancer in the study of a sample of 18,244 males, 45-64 years old, in Shanghai, China. The study also showed a unique gene-diet interaction. Subjects genetically deficient in an enzyme (GSTM1) that quickly eliminates isothiocyanates (ITCs) from the body got the most benefit from cruciferous vegetables, presumably because ITCs stayed around longer to confer their protective effect.

Since the subject of health eating was in the news today, Vidyya went in search of guidelines on the subject. Counseling adults and children over age 2 to limit dietary intake of fat (especially saturated fat) and cholesterol, maintain caloric balance in their diet, and emphasize foods containing fiber (i.e., fruits, vegetables, grain products) is recommended by the US Preventive Services Task Force. The full guidelines are available in this Vidyya.

In drug news, the FDA today proposed that all systemic antibacterial drug products intended for human use contain additional labeling information about the emergence of drug-resistant bacterial strains. New resistant strains are a major threat to future public health.

On the subject of drug resistance, for three decades, vancomycin has been the powerhouse therapy for certain life-threatening bacteria. Research now shows that with the widespread use of vancomycin, vancomycin-resistant organisms have emerged. Data from the Synercid as an Alternative to Vancomycin in Staph (S.A.V.S.) study presented at the 40th annual meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) shows that Synercid® (quinupristin/dalfopristin) I.V. is a potential alternative in cases where patients with a staphylococcal infection were unable to tolerate vancomycin's side effects, and where vancomycin did not eradicate the bacteria.

And finally, in cardiology news, two results from routine exercise tests can be combined to predict risk of death from all causes in adults over a five-year period, according to a Cleveland Clinic study published today in the Journal of the American Medical Association.

The articles in today's Vidyya are:

As always, we hope you enjoy the issue.

Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.